CHARLOTTE, N.C.—Dupilumab improves clinical, symptomatic, histologic and endoscopic aspects of eosinophilic esophagitis up to 24 weeks, with benefits sustained to 52 weeks, according to updated analyses of the phase 3 LIBERTY-EoE-TREET study.
In 2022, the FDA approved dupilumab (Dupixent, Sanofi/Regeneron) for the treatment of EoE in adults and adolescents aged 12 years and older and weighing at least 40 kg, based on previously reported data (UEG Week 2021, abstract LB10; Digestive Disease